MetaCap

Alnylam Pharmaceuticals Inc. (ALNY)

NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

143.82-4.00 (-2.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALNY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$19.26B
EPS (TTM)
$19.80
52-week range
143.40 – 479.79
Day range
143.40 – 151.41
Volume / Avg
2.33M / 2.09M
Beta
—

52-week range

$143.40$479.79

ALNY stock today

Shares of Alnylam Pharmaceuticals (ALNY) finished lower on Nov 20 at $143.82, a drop of 2.71% or $4.00 per share, versus the S&P 500's 3.70% decline. At this level, ALNY sits near the bottom of its 52-week range of $143.40 to $479.79: 70.0% below the high, set on Dec 3, 2025 and 0.3% above the low. ALNY is down 63.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.0%.

At 7.3x trailing earnings, Alnylam Pharmaceuticals trades below the peer-group median of 31.2x. Its forward P/E of 14.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Alnylam Pharmaceuticals

Company profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Headquarters
Cambridge, MA
Employees
2,500
IPO year
2004

Financial highlights

Full financials

In fiscal 2025, Alnylam Pharmaceuticals generated $3.71 billion in revenue, up 65.2% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $313.7 million, for a net margin of 8.4% versus a median of -101.0% in the prior 5 years. Gross margin was 81.8% (down from 86.4%) and operating margin 13.5%.

Alnylam Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.71B$2.25B$1.83B$1.04B$844.29M
Growth+65.19%+22.97%+76.23%+22.88%+71.31%
Net income$313.75M$-278.16M$-440.24M$-1.13B$-852.82M
EPS (diluted)$2.33$-2.18$-3.52$-9.30$-7.20

Analyst forecast

Forecast

Consensus (30 analysts)

buy

Avg. price target

$289.22+101.10%

  • Strong buy 7
  • Buy 14
  • Hold 9
  • Sell 0
  • Strong sell 0

Target range

Low $180.00High $410.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$15.72 vs $1.46
Surprise
+976.71%

ALNY news

All ALNY news

Alnylam Pharmaceuticals peers

Health Care sector
ALNY peer companies
CompanyPrice% ChgMarket capCompare
ASNDAscendis Pharma A/S252.73-1.26%$16.58Bvs ALNY
VTRSViatris Inc.19.63-1.26%$22.50Bvs ALNY
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs ALNY
BBIOBridgeBio Pharma Inc.76.03-2.75%$14.81Bvs ALNY
JAZZJazz Pharmaceuticals plc230.26-2.62%$14.78Bvs ALNY
ELANElanco Animal Health Incorporated25.74-2.09%$12.87Bvs ALNY
RDYDr. Reddy's Laboratories Ltd14.89+0.40%$12.41Bvs ALNY
BMRNBioMarin Pharmaceutical Inc.60.41-1.64%$11.70Bvs ALNY

Indexes, lists and sector

Alnylam Pharmaceuticals stock FAQ

What is Alnylam Pharmaceuticals's stock price today?

ALNY last traded at $143.82 as of Nov 20, 4:00 PM EST, down 2.71% on the day. Prices are delayed at least 15 minutes.

What is ALNY's P/E ratio?

ALNY trades at a trailing P/E ratio of 7.26 and a forward P/E of 14.51, compared with a median of 31.2 for its closest peers.

Is Alnylam Pharmaceuticals in the S&P 500?

No. Alnylam Pharmaceuticals is not currently a member of the S&P 500; it is included in the NDX.

Who is Alnylam Pharmaceuticals's CEO?

Dr. Yvonne L. Greenstreet M.B.A., M.D. is the chief executive officer of Alnylam Pharmaceuticals Inc., which has about 2,500 employees.

What is the ALNY 52-week high?

The 52-week high for ALNY is $479.79 and the 52-week low is $143.40. The stock is currently 70.0% below its high.

Compare ALNY